



Dr David Wheeler MD, FRCP

Hampstead Campus, Royal Free and University
College Medical School, Rowland Hill Street,
London, NW3 2PF, United Kingdom

e-mail: d.wheeler@medsch.ucl.ac.uk

Phone: +44-(0)20-7830-2930

Fax: +44-(0)20-7317-8591

David Wheeler was born in 1957 and graduated from Birmingham University Medical School in 1980. He received his clinical training in Birmingham, Leicester and Cardiff before undertaking 4 years of laboratory research, initially in London and subsequently in Boston, Massachusetts, funded by the UK Medical Research Council. His research interests include the role of dyslipidaemia in the progression of kidney damage, the cardiovascular complications of chronic kidney disease and the impact of the mineral bone disorder on the vascular system. He was appointed a Consultant Nephrologist at the University Hospital Birmingham in 1994 and moved to University College London in 2000 where he currently holds an academic position (Reader in Nephrology).

David is a member of the American Society of Nephrology, the International Society of Nephrology, the European Dialysis and Transplant Association and the UK Renal Association. He is immediate past chairman of UK Renal Association's Clinical Practice Guidelines Committee. Other roles include membership of the Advisory Board of the US Kidney Disease Outcomes Quality Initiative (K/DOQI) and of the Executive Committee of Kidney Disease: Improving Global Outcomes (KDIGO). Editorial responsibilities include previous terms as member of the editorial board of the American Journal of Kidney Disease and Journal of Renal Nutrition. He is currently a member of the editorial board of the Journal of the American Society of Nephrology, Deputy Editor of Nephron Clinical Practice as well as being one of two Deputy Editors of Nephrology Dialysis Transplantation.

Research activities include the role of UK National Coordinator of the Study of Heart and Renal Protection (SHARP), a randomized controlled trial designed to assess the impact of lipid lowering therapy on progression of kidney disease and cardiovascular event rates. He is also a member of the International Steering Committee of the EVAluation Of cinacalcet therapy to Lower cardioVascular Events (EVOLVE) trial. Current research funding covers clinical projects examining the determinants and consequences of arterial calcification in patients with chronic kidney disease and basic research assessing the impact of inflammation on intracellular cholesterol

homeostasis.

Declarations of interest:

- David Wheeler does not knowingly hold shares in any pharmaceutical company.
- In the past 3 years he has sat on Advisory Boards for AstraZenica, Amgen, Genzyme, Novartis and Shire Pharmaceuticals.
- He has consultancy agreements with Amgen (managed by University College London Consulting) relating to the EVOLVE and ARO studies. .

For the calendar year 2007:

He has received expenses to cover the cost of travel to and accommodation at scientific meetings from Roche (ATC May 2007) and Novartis (ASN November 2007).

He has received honoraria for lecturing and teaching from: Amgen, Genzyme, Roche and Novartis.

He has received research support from Amgen, Baxter, Genzyme and Roche.

His department has participated in studies funded by Amgen and Wyeth and has received an unrestricted grant from Roche to promote research. Basic research has been supported by the Baxter Extramural Grant programme.